Heidari Reza, Niknahad Hossein, Jamshidzadeh Akram, Eghbal Mohammad Ali, Abdoli Narges
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ; Gerash School of Paramedical Sciences,Shiraz University of Medical Sciences, Gerash, Iran.
Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ; Pharmacology and Toxicology Department, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Adv Pharm Bull. 2015 Mar;5(1):1-11. doi: 10.5681/apb.2015.001. Epub 2015 Mar 5.
Drug-induced liver injury (DILI) is a major problem for pharmaceutical industry and drug development. Mechanisms of DILI are many and varied. Elucidating the mechanisms of DILI will allow clinicians to prevent liver failure, need for liver transplantation, and death induced by drugs. Methimazole and propylthiouracil (PTU) are two convenient antithyroid agents which their administration is accompanied by hepatotoxicity as a deleterious side effect. Although several cases of antithyroid drugs-induced liver injury are reported, there is no clear idea about the mechanism(s) of hepatotoxicity induced by these medications. Different mechanisms such as reactive metabolites formation, oxidative stress induction, intracellular targets dysfunction, and immune-mediated toxicity are postulated to be involved in antithyroid agents-induced hepatic damage. Due to the idiosyncratic nature of antithyroid drugs-induced hepatotoxicity, it is impossible to draw a specific conclusion about the mechanisms of liver injury. However, it seems that reactive metabolite formation and immune-mediated toxicity have a great role in antithyroids liver toxicity, especially those caused by methimazole. This review attempted to discuss different mechanisms proposed to be involved in the hepatic injury induced by antithyroid drugs.
药物性肝损伤(DILI)是制药行业和药物研发中的一个重大问题。DILI的机制多种多样。阐明DILI的机制将使临床医生能够预防肝衰竭、肝移植需求以及药物所致的死亡。甲巯咪唑和丙硫氧嘧啶(PTU)是两种常用的抗甲状腺药物,其使用伴随着肝毒性这一有害副作用。尽管有几例抗甲状腺药物引起肝损伤的病例报道,但对于这些药物所致肝毒性的机制尚无明确认识。诸如活性代谢产物形成、氧化应激诱导、细胞内靶点功能障碍以及免疫介导毒性等不同机制被推测与抗甲状腺药物引起的肝损伤有关。由于抗甲状腺药物所致肝毒性具有特异质性,因此无法就肝损伤机制得出具体结论。然而,活性代谢产物形成和免疫介导毒性似乎在抗甲状腺药物肝毒性中起重要作用,尤其是由甲巯咪唑引起的肝毒性。本综述试图探讨所提出的与抗甲状腺药物引起肝损伤相关的不同机制。